However, a quite proportion of melanoma patients exhibit primary or acquired resistance (e.g., increased PD-L1 expression, impaired antigen presentation, or T-cell inactivation) resulting in 40%–65% failure in anti-PD-1 monotherapy and more than 70% failure in anti-CTLA-4 therapy (Gide et al., 2018). This evidence concerns the gene CD274 and melanoma.